Image Place holder

Lilit Karapetyan, MD, MS, FACP

Specialty: Hematology/Oncology
Program: Cutaneous Oncology


Cancer Focus: Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma

Dr. Lilit Karapetyan is an Assistant Member in the Department of Cutaneous Oncology, as well as an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Dr. Karapetyan received her MD degree from Yerevan State Medical University, Armenia, and her Master of Science degree in Clinical Research Design and Statistical Analysis at the University of Michigan. She completed an Internal Medicine Residency at Michigan State University. Dr. Karapetyan most recently completed a Hematology/ Oncology Fellowship at the University of Pittsburgh, Division of Hematology/Oncology, Hillman Cancer Center. Dr. Karapetyan’s clinical interest is in melanoma and other skin cancers, including understanding the risk for multiple primary melanomas. Her clinical research is focused on designing immunotherapy trials for patients with early stage and advanced melanoma. Her translational research is focused on identifying biomarkers for immunotherapy response with a specific interest in the role of tertiary lymphoid structures in affecting this response. She was the recipient of an ASCO Young Investigator Award in 2022.  

Education & Training


  • University of Pittsburgh - Hematology/Oncology


  • Yerevan State Medical University - Oncology
  • Michigan State University - Internal Medicine

Medical School:

  • Yerevan State Medical University - MD
Start Year: 2022 End Year: Conquer Cancer Merit Award, Sponsor: Conquer Cancer
Start Year: 2022 End Year: Conquer Cancer Young Investigator Award, Sponsor: Conquer Cancer
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Karapetyan L, Gooding W, Li A, Yang X, Knight A, Abushukair HM, Vargas De Stefano D, Sander C, Karunamurthy A, Panelli M, Storkus WJ, Tarhini AA, Kirkwood JM. Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma. Cancers (Basel). 2022 Oct.14(20). Pubmedid: 36291758. Pmcid: PMC9599365.
  • Karapetyan L, Yang X, Knight AD, Huang Z, Wang H, Sander CA, Minnier CP, Wilson M, Li A, Karunamurthy A, Storkus WJ, Kirkwood JM. Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer. 2022 Jun.128(11):2098-2106. Pubmedid: 35319783.
  • Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022 Dec.28(23):5030-5039. Pubmedid: 35579997. Pmcid: PMC9669281.
  • Karapetyan L, Luke JJ. Interferon biology and LAG3 shedding in PD-(L)1 plus LAG3 immunotherapy. Clin Cancer Res. 2022 Dec. Pubmedid: 36534010.
  • Yang X, Karapetyan L, Huang Z, Knight AD, Rajendran S, Sander C, Minnier CP, Wilson MJ, Kirkwood JM. Multiple primary melanoma in association with other personal and familial cancers. Cancer Med. 2022 Aug. Pubmedid: 35932099.


Title: Serum Tertiary Lymphoid Structure-Associated Cytokines/Chemokines as Biomarkers for Response to Immunotherapy and Development of Immune-Related Adverse Events in Melanoma Patients
Sponsor: Amer Society of Clinical Oncology (ASCO)
PI: Karapetyan, L.

Patient Comments
Overall Satisfaction

13 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments